Ibrexafungerp Citrate Drug Asset Due Diligence Report 2026

This Ibrexafungerp Citrate Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Approved

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: GO

Decision memo

Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.

The central underwriting question is whether Ibrexafungerp Citrate can convert its Small molecule drug profile and 1,3-beta-glucan synthase biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Ibrexafungerp Citrate (query alias: ibrexafungerp)
Modality / target	Small molecule drug; 1,3-beta-glucan synthase; 1,3-beta-glucan synthase inhibitors, Cell wall inhibitors
Highest global status	Approved
Originator	SCYNEXIS, Inc.
Active developers	GlaxoSmithKline LLC, Glaxosmithkline Plc /Suzhou Mfg. Facility/, Jiangsu Hansoh Pharmaceutical Group Co., Ltd.

The MCP disease footprint includes Candidiasis, Vulvovaginal, Aspergillosis, Candidiasis, Invasive. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
EUCTR2024-000382-25-3RD	Phase 1		6	Plasma PK parameters of ibrexafungerp including maximum concentration (Cmax) following first and the second dose, area under the concentration-time curve (AUC0-12, AUC12-24, and AUC12-∞), time to maximum concentration (Tmax) after the first and the second dose, and elimination half-life (t½) after the second dose, after receiving one day of BID oral doses of ibrexafungerp.
NCT05668429	Phase 1	Completed	6	Mass balance recovery
ISRCTN51111674	Phase 1	Ongoing	6	Not disclosed

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

Phase 1, Open-Label Pharmacokinetic Study in Healthy Lactating Women After Two Oral Doses of Ibrexafungerp Administered on a Single Day

Phase 1; n=5; evaluation: not stated. Reported fields: Pre-dose (Baseline)(Median) = 0 ng/mL (Full Range, 0 - 0); -; -

Open-Label Study to Evaluate the Efficacy and Safety of SCY-078 (Ibrexafungerp) in Patients With Fungal Diseases That Are Refractory to or Intolerant of Standard Antifungal Treatment (FURI)

Phase 3; n=233; evaluation: not stated. Reported fields: -; -; -

Efficacy and safety of oral ibrexafungerp in Chinese patients with vulvovaginal candidiasis: a phase III, randomized, double-blind study

Phase 3; n=360; evaluation: Positive. Reported fields: CCR = 25.6 % ; CCR = 51.0 %

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Ibrexafungerp Citrate addresses Candidiasis, Vulvovaginal, Aspergillosis, Candidiasis, Invasive. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The strongest market-validation signal in this screen is partner behavior: 4 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.

5. Transaction precedent and economics

Date	Transaction	Phase at deal	Disclosed economics
2023-03-30	GSK and SCYNEXIS announce an exclusive agreement to commercialise and further develop Brexafemme (ibrexafungerp), a novel, first-in-class medicine to treat fungal infection	Approved	US$90.0M upfront; US$503.0M milestones; US$593.0M stated total
2021-02-11	SCYNEXIS and Hansoh Pharma Announce Licensing Agreement and Strategic Partnership for Ibrexafungerp in Greater China	Phase 3	US$10.0M upfront
2013-09-10	SCYNEXIS Signs Deal With R-Pharm to Develop and Market Novel Antifungal Compound in Russia and Other Markets	Phase 1	Financial terms not disclosed

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Methods and compositions for immune control through dickkopf-1”. The milestone feed surfaced a patent-application signal described as “Antifungal agents, like ibrexafungerp for candida auris decolonization”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.

7. Principal risks and diligence gates

Therapeutic index across KRAS/BRAF mutation subgroups
On-target toxicity and adaptive MAPK resistance
Lack of matched efficacy results in the current MCP result set

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

GO